Neuland Laboratories Q2 Results Live : Neuland Laboratories declared their Q2 results on November 6, 2024, revealing a significant decline in both revenue and profit. The company’s topline decreased by 25.59% year-over-year, while profit saw a staggering drop of 63.2% compared to the same quarter last year.
In addition to the year-over-year decline, Neuland’s revenue also fell by 29.29% when compared to the previous quarter, with profit decreasing by 66.44%. This sharp decline raises concerns among investors about the company’s performance in a competitive market.
Despite a reduction in expenses, the company’s Selling, General & Administrative (SG&A) expenses were down by 13.77% quarter-over-quarter and decreased by 8.54% year-over-year. However, this was not enough to offset the drop in revenue and profit.
The operating income for Q2 also witnessed a considerable decline, down by 63.86% quarter-over-quarter and 62.47% year-over-year. This trend indicates ongoing challenges in maintaining profitability amidst fluctuating market conditions.
Earnings per share (EPS) for the quarter stood at ₹25.6, reflecting a 63.2% decrease from the previous year. This reduction further highlights the pressures faced by Neuland Laboratories as it navigates a difficult economic landscape.
On a more positive note, Neuland Laboratories has delivered a return of 2.43% over the past week, with an impressive 89.94% return over the last six months and a remarkable 167.7% year-to-date return, showcasing resilience in the long term.
Currently, Neuland Laboratories has a market capitalization of ₹18,173.86 Crore, with a 52-week high of ₹16,524.95 and a low of ₹4,718, indicating significant volatility in its stock price.
As of November 7, 2024, out of two analysts covering the company, one has given a Buy rating while the other has given a Strong Buy rating. The consensus recommendation reflects a Strong Buy as of this date, suggesting some optimism among analysts despite the recent downturn in results.
Neuland Laboratories Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 310.84 | 439.6 | -29.29% | 417.75 | -25.59% |
| Selling/ General/ Admin Expenses Total | 63.07 | 73.14 | -13.77% | 68.96 | -8.54% |
| Depreciation/ Amortization | 16.07 | 16.28 | -1.26% | 14.51 | +10.8% |
| Total Operating Expense | 264.69 | 311.9 | -15.14% | 294.77 | -10.2% |
| Operating Income | 46.15 | 127.71 | -63.86% | 122.98 | -62.47% |
| Net Income Before Taxes | 49.42 | 129.84 | -61.94% | 121.59 | -59.35% |
| Net Income | 32.84 | 97.87 | -66.44% | 89.25 | -63.2% |
| Diluted Normalized EPS | 25.6 | 64.16 | -60.1% | 69.56 | -63.2% |
